[{"arm_notes": "", "treatment_id": null, "treatment_name": "Eligible patients will be randomized into two arms either receiving standard of care only (control arm); or standard of care and inhaled Nitric Oxide (iNO) using a helmet or tight sealing oronasal mask (case arm). iNO will be deluvered as pulses lasting for 30 min at 12 h intervals; for 3 consecutive days. iNO will be administered at the minimum FiO2 to maintain saturations above 92%; using a V60 bilevel positive airway pressure (BiPAP) machine. The flow rates will be titrated to administer escalating doses of iNO starting from 10 ppm to 80 ppm over a period of 30 min. Following this iNO will be weaned off at the rate of 10 ppm per min. Study patients will be started on oral Sildenafil 10 mg TID for 5 days; to prevent rebound rise in pulmonary pressures after iNO discontinuation; provided their MAP is >60 mmHg. Standard of care therapies including antivirals; steroids; anticoagulants; and other medications will be administered in both study arms as per institutional protocol.", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 890, "treatment_name": "Nitric oxide gas", "treatment_type": "Gas inhalation", "pharmacological_treatment": "Non pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2188, "treatment_name": "Standard of care", "treatment_type": "Standard of care", "pharmacological_treatment": "Standard of care"}]